Natalie Tomaszewski1, Xulei He1, Victoria Solomon1, Mitchell Lee1, Wendy J Mack2, Joseph F Quinn3, Meredith N Braskie4, Hussein N Yassine1,4. 1. Department of Medicine, University of Southern California, Los Angeles, CA, USA. 2. Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA. 3. Department of Neurology, Oregon Health and Science University, Portland VA Medical Center, Portland, OR, USA. 4. Imaging Genetics Center, Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Abstract
BACKGROUND:Docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and arachidonic acid (AA) play key roles in several metabolic processes relevant to Alzheimer's disease (AD) pathogenesis and neuroinflammation. Carrying the APOEɛ4 allele (APOE4) accelerates omega-3 polyunsaturated fatty acid (PUFA) oxidation. In a pre-planned subgroup analysis of the Alzheimer's Disease Cooperative Study-sponsored DHA clinical trial, APOE4 carriers with mild probable AD had no improvements in cognitive outcomes compared to placebo, while APOE 4 non-carriers showed a benefit from DHA supplementation. OBJECTIVE: We sought to clarify the effect of APOEɛ4/ɛ4 on both the ratio of plasma DHA and EPA to AA, and on hippocampal volumes after DHA supplementation. METHODS:Plasma fatty acids and APOE genotype were obtained in 275 participants randomized to 18 months of DHA supplementation or placebo. A subset of these participants completed brain MRI imaging (n = 86) and lumbar punctures (n = 53). RESULTS: After the intervention, DHA-treated APOEɛ3/ɛ3 and APOEɛ2/ɛ3 carriers demonstrated significantly greater increase in plasma DHA/AA compared to ɛ4/ɛ4 carriers. APOEɛ2/ɛ3 had a greater increase in plasma EPA/AA and less decline in left and right hippocampal volumes compared to compared to ɛ4/ɛ4 carriers. The change in plasma and cerebrospinal fluid DHA/AA was strongly correlated. Greater baseline and increase in plasma EPA/AA was associated with a lower decrease in the right hippocampal volume, but only in APOE 4 non-carriers. CONCLUSION: The lower increase in plasma DHA/AA and EPA/AA in APOEɛ4/ɛ4 carriers after DHA supplementation reduces brain delivery and affects the efficacy of DHA supplementation.
RCT Entities:
BACKGROUND:Docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and arachidonic acid (AA) play key roles in several metabolic processes relevant to Alzheimer's disease (AD) pathogenesis and neuroinflammation. Carrying the APOEɛ4 allele (APOE4) accelerates omega-3 polyunsaturated fatty acid (PUFA) oxidation. In a pre-planned subgroup analysis of the Alzheimer's Disease Cooperative Study-sponsored DHA clinical trial, APOE4 carriers with mild probable AD had no improvements in cognitive outcomes compared to placebo, while APOE 4 non-carriers showed a benefit from DHA supplementation. OBJECTIVE: We sought to clarify the effect of APOEɛ4/ɛ4 on both the ratio of plasma DHA and EPA to AA, and on hippocampal volumes after DHA supplementation. METHODS:Plasma fatty acids and APOE genotype were obtained in 275 participants randomized to 18 months of DHA supplementation or placebo. A subset of these participants completed brain MRI imaging (n = 86) and lumbar punctures (n = 53). RESULTS: After the intervention, DHA-treated APOEɛ3/ɛ3 and APOEɛ2/ɛ3 carriers demonstrated significantly greater increase in plasma DHA/AA compared to ɛ4/ɛ4 carriers. APOEɛ2/ɛ3 had a greater increase in plasma EPA/AA and less decline in left and right hippocampal volumes compared to compared to ɛ4/ɛ4 carriers. The change in plasma and cerebrospinal fluid DHA/AA was strongly correlated. Greater baseline and increase in plasma EPA/AA was associated with a lower decrease in the right hippocampal volume, but only in APOE 4 non-carriers. CONCLUSION: The lower increase in plasma DHA/AA and EPA/AA in APOEɛ4/ɛ4 carriers after DHA supplementation reduces brain delivery and affects the efficacy of DHA supplementation.
Authors: C R Jack; R C Petersen; Y C Xu; P C O'Brien; G E Smith; R J Ivnik; B F Boeve; S C Waring; E G Tangalos; E Kokmen Journal: Neurology Date: 1999-04-22 Impact factor: 9.910
Authors: Giovanni B Frisoni; Clifford R Jack; Martina Bocchetta; Corinna Bauer; Kristian S Frederiksen; Yawu Liu; Gregory Preboske; Tim Swihart; Melanie Blair; Enrica Cavedo; Michel J Grothe; Mariangela Lanfredi; Oliver Martinez; Masami Nishikawa; Marileen Portegies; Travis Stoub; Chadwich Ward; Liana G Apostolova; Rossana Ganzola; Dominik Wolf; Frederik Barkhof; George Bartzokis; Charles DeCarli; John G Csernansky; Leyla deToledo-Morrell; Mirjam I Geerlings; Jeffrey Kaye; Ronald J Killiany; Stephane Lehéricy; Hiroshi Matsuda; John O'Brien; Lisa C Silbert; Philip Scheltens; Hilkka Soininen; Stefan Teipel; Gunhild Waldemar; Andreas Fellgiebel; Josephine Barnes; Michael Firbank; Lotte Gerritsen; Wouter Henneman; Nikolai Malykhin; Jens C Pruessner; Lei Wang; Craig Watson; Henrike Wolf; Mony deLeon; Johannes Pantel; Clarissa Ferrari; Paolo Bosco; Patrizio Pasqualetti; Simon Duchesne; Henri Duvernoy; Marina Boccardi Journal: Alzheimers Dement Date: 2014-09-27 Impact factor: 21.566
Authors: R Chouinard-Watkins; C Rioux-Perreault; M Fortier; J Tremblay-Mercier; Y Zhang; P Lawrence; M C Vohl; P Perron; D Lorrain; J T Brenna; S C Cunnane; M Plourde Journal: Br J Nutr Date: 2013-04-30 Impact factor: 3.718
Authors: M Vieira; J Fernandes; A Burgeiro; G M Thomas; R L Huganir; C B Duarte; A L Carvalho; A E Santos Journal: Neurobiol Dis Date: 2010-08-12 Impact factor: 5.996
Authors: Hussein N Yassine; Meredith N Braskie; Wendy J Mack; Katherine J Castor; Alfred N Fonteh; Lon S Schneider; Michael G Harrington; Helena C Chui Journal: JAMA Neurol Date: 2017-03-01 Impact factor: 18.302
Authors: Hussein N Yassine; Varun Rawat; Wendy J Mack; Joseph F Quinn; Karin Yurko-Mauro; Eileen Bailey-Hall; Paul S Aisen; Helena C Chui; Lon S Schneider Journal: Alzheimers Res Ther Date: 2016-06-30 Impact factor: 6.982
Authors: Bolun Li; Jie Shi; Boris A Gutman; Leslie C Baxter; Paul M Thompson; Richard J Caselli; Yalin Wang Journal: PLoS One Date: 2016-04-11 Impact factor: 3.240
Authors: Shaowei Wang; Boyang Li; Victoria Solomon; Alfred Fonteh; Stanley I Rapoport; David A Bennett; Zoe Arvanitakis; Helena C Chui; Patrick M Sullivan; Hussein N Yassine Journal: Mol Neurodegener Date: 2022-06-15 Impact factor: 18.879
Authors: Gillian Coughlan; Ryan Larsen; Min Kim; David White; Rachel Gillings; Michael Irvine; Andrew Scholey; Neal Cohen; Cristina Legido-Quigley; Michael Hornberger; Anne-Marie Minihane Journal: Brain Commun Date: 2021-05-11
Authors: Stan G Louie; Hussein N Yassine; Brandon Ebright; Isaac Assante; Roy A Poblete; Shaowei Wang; Marlon V Duro; David A Bennett; Zoe Arvanitakis Journal: Alzheimers Res Ther Date: 2022-10-11 Impact factor: 8.823
Authors: Sarah B Scheinman; Dhavamani Sugasini; Monay Zayed; Poorna C R Yalagala; Felecia M Marottoli; Papasani V Subbaiah; Leon M Tai Journal: Front Neurosci Date: 2021-07-01 Impact factor: 4.677